Cargando…
Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation
Pharmacogenetics is the study of genetic basis in the individual response to drugs. A thorough knowledge of this will lead to a future where tailor-made drugs, suiting an individual, can be used. Scandinavian countries have been known for wide usage of pharmacogenetics and the most widely used appli...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910954/ https://www.ncbi.nlm.nih.gov/pubmed/20680157 http://dx.doi.org/10.4103/0971-6866.55221 |
_version_ | 1782184433730715648 |
---|---|
author | Kalra, Kapil Jarmal, Garima Mishra, Neeti |
author_facet | Kalra, Kapil Jarmal, Garima Mishra, Neeti |
author_sort | Kalra, Kapil |
collection | PubMed |
description | Pharmacogenetics is the study of genetic basis in the individual response to drugs. A thorough knowledge of this will lead to a future where tailor-made drugs, suiting an individual, can be used. Scandinavian countries have been known for wide usage of pharmacogenetics and the most widely used application is for genotyping CYP2D6 in treating psychiatric illness. The CYP-450 enzyme, a super family of microsomal drug-metabolizing enzymes, is the most important of enzymes that catalyzes phase-I drug metabolism reaction. CYP2D6 is a member of this family and it has been most intensively studied and the best example of pharmacogenetics variation in drug metabolism. Neuro-transmitter and drug acting CNS viz. codeine, dextromethorphan, metoprolol and tryptyline etc. are well metabolized by this enzyme. Thus, CYP2D6 is one of the most important and responsible enzymes which regulates bioavailability and metabolism of drug. Presently 75 alleles of CYP2D6 have been described which are responsible for variance of metabolism and toxicity of drugs. Thus, by determining variance of CYP2D6 using molecular approaches viz., PCR, real-time PCR, DNA micro-array and molecular docking can determine the adverse effects, drug toxicity, bioavailability and therapeutic potential of new drug. |
format | Text |
id | pubmed-2910954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-29109542010-08-02 Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation Kalra, Kapil Jarmal, Garima Mishra, Neeti Indian J Hum Genet Review Article Pharmacogenetics is the study of genetic basis in the individual response to drugs. A thorough knowledge of this will lead to a future where tailor-made drugs, suiting an individual, can be used. Scandinavian countries have been known for wide usage of pharmacogenetics and the most widely used application is for genotyping CYP2D6 in treating psychiatric illness. The CYP-450 enzyme, a super family of microsomal drug-metabolizing enzymes, is the most important of enzymes that catalyzes phase-I drug metabolism reaction. CYP2D6 is a member of this family and it has been most intensively studied and the best example of pharmacogenetics variation in drug metabolism. Neuro-transmitter and drug acting CNS viz. codeine, dextromethorphan, metoprolol and tryptyline etc. are well metabolized by this enzyme. Thus, CYP2D6 is one of the most important and responsible enzymes which regulates bioavailability and metabolism of drug. Presently 75 alleles of CYP2D6 have been described which are responsible for variance of metabolism and toxicity of drugs. Thus, by determining variance of CYP2D6 using molecular approaches viz., PCR, real-time PCR, DNA micro-array and molecular docking can determine the adverse effects, drug toxicity, bioavailability and therapeutic potential of new drug. Medknow Publications 2009 /pmc/articles/PMC2910954/ /pubmed/20680157 http://dx.doi.org/10.4103/0971-6866.55221 Text en © Indian Journal of Human Genetics http://creativecommons.org/licenses/by-nc-sa/2.0 This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Kalra, Kapil Jarmal, Garima Mishra, Neeti Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation |
title | Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation |
title_full | Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation |
title_fullStr | Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation |
title_full_unstemmed | Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation |
title_short | Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation |
title_sort | drugs impact on cyp-450 enzyme family: a pharmacogenetical study of response variation |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910954/ https://www.ncbi.nlm.nih.gov/pubmed/20680157 http://dx.doi.org/10.4103/0971-6866.55221 |
work_keys_str_mv | AT kalrakapil drugsimpactoncyp450enzymefamilyapharmacogeneticalstudyofresponsevariation AT jarmalgarima drugsimpactoncyp450enzymefamilyapharmacogeneticalstudyofresponsevariation AT mishraneeti drugsimpactoncyp450enzymefamilyapharmacogeneticalstudyofresponsevariation |